Day: November 10, 2022

Archbishop Chrysostomos will lie in state from Thursday until Saturday when his funeral service will be held on Saturday at St. Varnavas church.

The book of condolences remains open at the Archbishopric. Archbishop Chrysostomos passed away on Monday morning at the age of 81 following a four year battle with cancer.

The funeral will be officiated by Ecumenical Patriach Bartholomew who is visiting Cyprus for the first time.

It will also be attended by President of the Hellenic Republic Katerina Sakelaropoulou while Cyprus President Nicos Anastasiades will deliver the eulogy.

The late Archbishop will be buried in a crypt located under the newly constructed church, as was his request.

Source: Cyprus News Agency

Cyprus Shipping Deputy Minister Vasilios Demetriades is set to present before the Cyprus – Israel business forum the strategy, actions and initiatives promoted by Cyprus for shipping, highlighting the advantages of Cyprus as a quality shipping center.

In press release, the Deputy Ministry said Demetriades travelled to Israel on Thursday to attend the forum.

During the forum, organised by the Ministry of Energy, Commerce and Industry, in cooperation with the Cyprus Chamber of Commerce and Industry and the corresponding Federation of Chambers of Commerce of Israel, the Deputy Minister of Shipping will present the strategy, actions and initiatives promoted by Cyprus for shipping, highlighting the advantages of Cyprus as a quality shipping center.

In addition, Demetriades will outline the investment prospects and opportunities for developing business partnerships between the two countries in various sectors of the Blue Economy.

Source: Cyprus News Agency

MONTERREY, Mexico–(BUSINESS WIRE)– CEMEX, S.A.B. de C.V. (“CEMEX”) announced today that it is among the first companies in the global cement industry to validate its 2030 decarbonization goals through the Science Based Targets initiative (SBTi) for alignment under their new 1.5ºC scenario, the most ambitious pathway defined for the industry. This validation includes scope 1, 2, and 3 targets.

CEMEX, the largest concrete producer in the western world and a global leader in cement production, accelerated it decarbonization efforts through its Future in Action program in 2021, aiming to build a more sustainable, circular future, with the primary objective of becoming a net-zero CO2 company. Since then, the company has achieved record-breaking CO2 reductions, and its performance to date has given the company the confidence that it can achieve a more accelerated pathway for 2030.

“Climate change is the biggest challenge of our times, and the building materials industry must be at the forefront of decarbonizing the built environment,” said Fernando A. González, CEO of CEMEX. “We are committed to being leaders on the path to net-zero through relentless innovation and aggressive targets that are backed up by meaningful and measurable progress. The SBTi’s validation is clear evidence of this. Through Future in Action, we are reducing carbon emissions in every part of our value chain and providing our customers with lower carbon products so they can also be part of the solution.”

“Climate science tells us that we need rapid and deep emissions cuts if we are to achieve global net-zero,” said Luiz Amaral, Chief Executive Officer of the Science Based Targets initiative. “Today, CEMEX joins the growing list of companies cutting emissions across its entire value chain in line with science and it is playing its part in limiting warming to 1.5°C.”

For more information about CEMEX’s targets, please visit www.cemex.com/sustainability/future-in-action

For more information about SBTi, please visit www.sciencebasedtargets.org

CEMEX (NYSE: CX) is a global construction materials company that is building a better future through sustainable products and solutions. CEMEX is committed to achieving carbon neutrality through relentless innovation and industry-leading research and development. CEMEX is at the forefront of the circular economy in the construction value chain and is pioneering ways to increase the use of waste and residues as alternative raw materials and fuels in its operations with the use of new technologies. CEMEX offers cement, ready-mix concrete, aggregates, and urbanization solutions in growing markets around the world, powered by a multinational workforce focused on providing a superior customer experience, enabled by digital technologies. For more information, please visit: cemex.com

CEMEX assumes no obligation to update or correct the information contained in this press release. This press release contains forward-looking statements within the meaning of the U.S. federal securities laws. CEMEX intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the U.S. federal securities laws. These forward-looking statements reflect CEMEX’s current expectations and projections about future events based on CEMEX’s knowledge of present facts and circumstances and assumptions about future events, as well as CEMEX’s current plans based on such facts and circumstances. These statements necessarily involve risks and uncertainties that could cause actual results to differ materially from CEMEX’s expectations. The content of this press release is for informational purposes only, and you should not construe any such information or other material as legal, tax, investment, financial, or other advice. CEMEX is not responsible for the content of any third-party website or webpage referenced to or accessible through this press release.

Source: Cyprus News Agency

Proposals, which could form the basis for undertaking an initiative for the Cyprus issue, were presented by President of the Republic, Nicos Anastasiades, during a working meeting he held on Thursday, in Paris, with French President Emmanuel Macron.

According to a press release by the Presidency of the Republic of Cyprus, President Anastasiades informed President Macron about the latest developments in the Cyprus issue, thanking him for Frances’ firm position of principles in favor of a comprehensive solution of a bizonal bicommunal federation, as defined by the relevant UN Security Council resolutions, and a solution that should ensure the full implementation of the European acquis and the values of the European Union, as well as human rights.

He also expressed deep gratitude for his valuable support whenever Cyprus-related issues are discussed at the United Nations, the European Union, or in EUMED 9, and in other fora.

It is added that in the light of the rapidly changing geopolitical environment following the Russian invasion of Ukraine, President Anastasiades conveyed to President Macron his strong concern that, as long as the Cyprus problem remains unresolved, it will continue to be a threat to peace and security, not only in the fragile region of the Eastern Mediterranean, but also in Europe in general.

It is added that President Anastasiades “submitted some proposals to President Macron which would be able to help, on the one hand, in the de-escalation and in general the avoidance of tensions or the creation of new faits accomplis on land or at sea and, on the other hand, in the creation, through appropriate preparation, of those necessary conditions for the resumption of a fruitful dialogue for the settlement of the Cyprus issue, always under the auspices of the United Nations.

“The proposals in question, which could form the basis for taking an initiative, provide in the first stage for a more active and in good faith involvement of partners who have a role to play in the Cyprus issue, including of course France, always in consultation with the United Nations” the press release says.

“And of course”, it is added, “as soon as conditions allow, there could be the active involvement of the European Union, with the aim of assisting all those involved in the effort to find a functional and sustainable solution that will benefit all Cypriot citizens, Greek Cypriots and Turkish Cypriots. Besides, Cyprus is a Member State of the European Union and the solution of the Cyprus problem is also a European matter.”

During the meeting, President Anastasiades assured President Macron that until the last day of his term in office as President of the Republic of Cyprus, he will continue to work for the peaceful resolution of the Cyprus problem, in accordance with International Law.

He also conveyed to the French President his warm thanks and his sincere appreciation for the excellent cooperation “but also a close friendship that contributed to the further strengthening of relations between Cyprus and France, both at the bilateral level in an ever-expanding range of areas of common interest and within the common European family.”

Furthermore, the two Presidents analyzed the dynamics and strategic depth of the mutually beneficial cooperation between the two countries.

“Within this framework, special reference is made on the prospects in the Defence and Security, Education, as well as Energy sectors” the Presidency says.

President Anastasiades reiterated that France is one of the most important partners of the Republic of Cyprus, a strategic partner, contributing the most to Cyprus’ efforts to create conditions of security, peace and stability in the Eastern Mediterranean region.

They also discussed the current challenges in relation to the ongoing war in Ukraine. The President was briefed by Macron on the latest dramatic developments, as well as on any prospects for ending the hostilities. It is noted finally that the French President since the beginning had actively undertaken and continues to undertake very important initiatives with the aim of reaching a peace agreement.

Source: Cyprus News Agency

The number Ukrainians fleeing the Russian invasion of their country that have received temporary protection status in the European Union fell in September in 18 of the 25 EU Member States with available data, while Cyprus was the country that saw the third largest increase during the same period, according to data released by Eurostat, the statistical service of the EU.

In September 2022, Poland granted the highest number of temporary protection statuses to Ukrainians (53,545) followed by Germany (51,980), Romania (9,715), Spain (5,745) and Ireland (4,925).

Also in September, a total of 770 Ukrainian citizens were granted temporary protection status in Cyprus. Most temporary protection permits in Cyprus were granted in April (2,740), in May (3,170) and in June (2,140).

The largest decreases in September compared to August were observed in Poland (-13,735 people compared with August 2022), followed by Germany (-10,160) and France (-2,830).

Meanwhile, the highest increases were recorded in Ireland (+900), Denmark (+345) and Cyprus (+105). Minor increases (+10 or less) were recorded in Luxembourg, Malta and Romania. No changes were recorded in Bulgaria.

However, until 30 September, Poland reported the highest number of Ukrainian beneficiaries of temporary protection with a total of 1.4 million, followed by Germany (813,725 Ukrainian beneficiaries), Spain (145,825) and Bulgaria (134,790).

Compared with the population of each Member State, the highest ratio of Ukrainian citizens granted temporary protection in September 2022 per thousand inhabitants was recorded in Estonia (1.8 granted temporary protection per thousand inhabitants), followed by Poland (1.4) and Lithuania, Latvia and Ireland (all 1.0).

Germany granted the highest number of temporary protections for Ukrainian children (persons under 18 years old) with a total of 15,460 (representing 30% of Ukrainians granted protection in Germany in September 2022), followed by Poland (13,980 or 26%) and Romania (2,865 or 29%).

Notably, in all countries for which September 2022 data are available, children below the age of 14 represented between 61% to 87% of all children granted temporary protection.

Also, according to the same data, the majority of Ukrainians granted temporary protection were females, including girls. The largest numbers of females who received temporary protection were reported by Poland (33,650, representing 63% of Ukrainians granted protection in Poland in September), Germany (30,785 or 59%) and Romania (5,605, or 58%).

Similarly, the largest numbers of males who received temporary protection were also reported by Germany (21,110 or 41%), Poland (19,900 or 37%) and Romania (4,115 or 42%).

Source: Cyprus News Agency

Cyprus President, Nicos Anastasiades will have on Thursday a meeting in Paris with his French counterpart, Emmanuel Macron. According to a written statement by the Director of the President’s Press Office, Andreas Iosif, Anastasiades will discuss with Macron about the current situation as regards the Cyprus problem and the proposal for the EU to undertake an initiative on the issue in cooperation with the UN for the resumption of the process for a Cyprus settlement.

According to the Cypriot Presidency, the meeting will take place at 1745 (Cyprus time) at the presidential office.

It will also be attended by Government Spokesman, Marios Pelekanos, the Ambassador of Cyprus to France, George Shakallis and the Director of the President’s office, Pantelis Pantelides.

Cyprus has been divided since 1974, when Turkish troops invaded and occupied 37% of its territory.

Repeated rounds of UN-led peace talks have so far failed to yield results. The latest round of negotiations, in July 2017 at the Swiss resort of Crans-Montana ended inconclusively.

Source: Cyprus News Agency

Seagen Names David R. Epstein as Chief Executive Officer and Director

-Roger Dansey, M.D., Appointed President, Research and Development –

BOTHELL, Wash.–(BUSINESS WIRE)– Seagen Inc. (Nasdaq: SGEN) today announced that its Board of Directors has appointed David R. Epstein as Chief Executive Officer (CEO) and a member of the Board of Directors. Mr. Epstein brings more than 30 years of experience in the biopharmaceutical industry, including more than 25 years at Novartis where he built its oncology business unit from initiation to second largest in the world and then served as CEO of Novartis Pharmaceuticals, a division of Novartis AG. More recently, he was executive partner at Flagship Pioneering. In addition, Seagen announced that Roger Dansey, M.D., who has served as Seagen’s Chief Medical Officer (CMO) since 2018 and as Interim CEO since May 2022, has been appointed President, Research and Development. In this new role, Dr. Dansey will continue to serve as CMO reporting to David.

“Following a comprehensive search process, the Board selected David to serve as Seagen’s next CEO. He shares Seagen’s belief that our future is bright as we continue to build world-class capabilities in order to develop and commercialize new innovative treatments that improve the lives of patients with cancer. David’s demonstrated ability to build and scale a global oncology business, his experience in both large multi-faceted organizations and small biotechnology startups, combined with deep oncology knowledge, provide the strategic and operational expertise needed to lead Seagen to the next level,” said Felix J. Baker, Ph.D., Chair of the Board. “We are extremely grateful for Roger’s successful leadership and dedication as interim CEO. We look forward to Roger being able to focus his efforts on further strengthening our early research efforts, as he has successfully done for development, and driving the innovative engine that has been the heart of Seagen to have an even greater impact on cancer patients in the future.”

Mr. Epstein said, “I have long admired Seagen as a leader in the development and commercialization of transformative cancer therapies. Seagen is a pioneer in antibody-drug conjugate (ADC) technology with a portfolio of four approved medicines, a diverse pipeline of promising programs, and a science-driven, patient-first culture. I am honored to become CEO and work with the experienced team to further deliver on Seagen’s mission to make a meaningful difference so that people who have been diagnosed with cancer can live better lives.”

“I welcome David to the Seagen team and look forward to working closely with him as we continue to bring forward novel ADCs and other targeted treatments for cancer patients,” said Dr. Dansey. “I am excited to bring my passion for science and innovation to my expanded role overseeing research and development as we continue to deliver on the full potential of our pipeline and programs.”

About David R. Epstein

David R. Epstein has more than 30 years of drug development, deal making, commercialization and people leadership experience on a global scale. Most recently, he was executive partner at Flagship Pioneering, a builder of breakthrough bioplatform companies. From 2010 to mid-2016 he served as CEO of Novartis Pharmaceuticals, a division of Novartis AG. Previously, David started and led Novartis’ Oncology and Molecular Diagnostic units. Over the course of his career, he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx and Entresto. Mr. Epstein holds a B.S. Degree in Pharmacy from Rutgers University College of Pharmacy and an MBA in Finance and Marketing from the Columbia University Graduate School of Business.

About Roger Dansey, M.D.

Dr. Dansey joined Seagen as CMO in 2018, bringing extensive experience in cancer drug development. Previously, he was Therapeutic Area Head for Late-Stage Oncology at Merck & Co., Inc., where he was responsible for registration efforts for Keytruda (pembrolizumab) across multiple tumor types. Earlier in his career, Dr. Dansey was the Vice President of Oncology Clinical Research at Gilead Sciences and the Global Development Lead for Xgeva (denosumab) at Amgen, where he held multiple roles in oncology and hematology.

About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit and follow @SeagenGlobal on Twitter.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the potential of Seagen’s pipeline and programs, and the company’s efforts to build world-class capabilities in order to develop and commercialize new innovative treatments and to bring forward novel ADCs and other targeted treatments for cancer patients. Factors that may cause such a difference include, without limitation, the difficulty and uncertainty of pharmaceutical product development, the risk of adverse events or safety signals, the inability to show sufficient activity in clinical trials and the possibility of adverse regulatory actions. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Source: Cyprus News Agency